Related Experiment Videos
Technology evaluation: omalizumab, Genentech/Novartis/Tanox
1University of Pennsylvania Medical Center, Pulmonary, Allergy and Critical Care Division, 852 BRB II/III, 421 Curie Boulevard, Philadelphia, PA 19104-6160, USA. alazaar@mail.med.upenn.edu
Current Opinion in Molecular Therapeutics
|April 3, 2003
Summary
Omalizumab, an anti-immunoglobulin E antibody, is being developed for allergic rhinitis and asthma. This targeted therapy is progressing through clinical trials and regulatory reviews globally.
Area of Science:
- Immunology
- Pharmacology
- Clinical Medicine
Background:
- Allergic rhinitis and asthma are significant global health concerns.
- Current treatments have limitations, necessitating novel therapeutic approaches.
- Immunoglobulin E (IgE) plays a central role in allergic inflammation.
Purpose of the Study:
- To evaluate the efficacy and safety of omalizumab for allergic rhinitis and asthma.
- To advance the development of a targeted biologic therapy for allergic diseases.
Main Methods:
- Co-development of a humanized monoclonal antibody, omalizumab, targeting IgE.
- Conducting Phase II and Phase III clinical trials in multiple countries.
- Seeking regulatory approval for therapeutic use.
Main Results:
- Omalizumab is progressing through advanced clinical trials (Phase II and III).
- The antibody has reached the pre-registration stage in major markets including the US and Europe.
- Omalizumab is already registered for allergic rhinitis and asthma in Australia.
Conclusions:
- Omalizumab demonstrates potential as an effective treatment for allergic rhinitis and asthma.
- The drug's global development and registration indicate promising therapeutic value.
- Targeting IgE represents a key strategy in managing allergic conditions.